Table 3. Post-hoc associations between clinicopathological variables and pCR or 4th-cycle ORR.

Variables	N	pCR [n (%)]		P		4th-cycle ORR [n (%)]		P
		tpCR	Non-tpCR			ORR	Non-ORR
pCR, complete pathological response; ORR, objective response rate; HR, hormone receptor; TOP2A, topoisomerase 2 alpha; IHC, immunohistochemistry; tpCR, total pathological complete response.
Overall population	78	47 (60.3)	31 (39.7)	−		60 (76.9)	18 (23.1)	−
Age (year)				0.509				0.315
<40	18	9 (50.0)	9 (50.0)			15 (83.3)	3 (16.7)
40−50	27	16 (59.3)	11 (40.7)			18 (66.7)	9 (33.3)
>50	33	22 (66.7)	11 (33.3)			27 (81.8)	6 (18.2)
Menopausal status				0.227				0.134
Premenopausal	49	27 (55.1)	22 (44.9)			35 (71.4)	14 (28.6)
Postmenopausal	29	20 (69.0)	9 (31.0)			25 (86.2)	4 (13.8)
HR status				0.305				0.168
Negative	28	19 (67.9)	9 (32.1)			24 (85.7)	4 (14.3)
Positive	50	28 (56.0)	22 (44.0)			36 (72.0)	14 (28.0)
Histological grade				0.152				0.454
II	26	16 (61.5)	10 (38.5)			20 (76.9)	6 (23.1)
II−III	3	0 (0)	3 (100)			2 (66.7)	1 (33.3)
III	18	13 (72.2)	5 (27.8)			12 (66.7)	6 (33.3)
Unknown	31	18 (58.1)	13 (41.9)			26 (83.9)	5 (16.1)
Regional lymph node status				0.346				0.683
Negative	23	12 (52.2)	11 (47.8)			17 (73.9)	6 (26.1)
Positive	55	35 (63.6)	20 (36.4)			43 (78.2)	12 (21.8)
T stage				0.870				0.569
T1−2	52	31 (59.6)	21 (40.4)			41 (78.8)	11 (21.2)
T3−4	26	16 (61.5)	10 (38.5)			19 (73.1)	7 (26.9)
N stage				0.346				0.683
N0	23	12 (52.2)	11 (47.8)			17 (73.9)	6 (26.1)
N1−3	55	35 (63.6)	20 (36.4)			43 (78.2)	12 (21.8)
Clinical stage				0.277				0.441
II	55	31 (56.4)	24 (43.6)			41 (74.5)	14 (25.5)
III	23	16 (69.6)	7 (30.4)			19 (82.6)	4 (17.4)
TOP2A IHC expression				0.103				0.489
≤15%	15	7 (46.7)	8 (53.3)			13 (86.7)	2 (13.3)
>15%	54	32 (59.3)	22 (40.7)			41 (75.9)	13 (24.1)
Unknown	9	8 (88.9)	1 (11.1)			6 (66.7)	3 (33.3)